Resources

A 64-year-old female presents to your office for her 3-month follow-up. She has previously been diagnosed with mild diastolic heart failure, secondary to hypertension. She currently takes an ace-inhibitor and a diuretic with good control of her heart failure symptoms and hypertension. At her last visit, she had a FPG 118 mg/dl. In a subsequent conversation with her, you discussed how she has developed prediabetes and suggested lifestyle modifications. Since her last visit, she has taken up very gentle walking four times/week and has changed her diet to a more healthful one. Despite these positive changes, this visit’s labs return an A1C 7.8%; her remaining labs are within normal limits. Which one of the following antihyperglycemic medication classes would you choose to initiate treatment? A. Sulfonylureas B. Biguanides C. Insulin D. Thiazolidinediones Follow the link for the answer.

In treating your patients with diabetes who have hypertension, elevated blood sugars, and elevated LDL’s, do you treat 1 or 2 of the comorbidities or all 3 at the same time? Follow the link to share your response.

Dr. Mark O. Huising completed his formal education in the Netherlands, where he spent his PhD studying the evolution of immune and endocrine systems in early vertebrates.

Mark Huising discusses his ADA symposium on “Neglected Delta Cell: The Difference Delta Cells Make in Glucose Control," and the nature and importance of delta cells in diabetes research.

In this Exclusive Interview, Dr. Mark Huising talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about his work in delta cells, their impact on the body as well as diabetes, and the importance of imparting an understanding about these cells to the diabetes community, patients and medical professionals alike.

In part 1 of this Exclusive Interview, Dr. Mark Huising talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the function of delta cells and what precipitated his work in this field.

In part 2 of this Exclusive Interview, Dr. Mark Huising talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the impact of type 2 on delta cells and measuring the activity of these cells.

In part 3 of this Exclusive Interview, Dr. Mark Huising talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the impact of diabetes medications on delta cell activity.

In part 4 of this Exclusive Interview, Dr. Mark Huising explains the benefit of his research for those with diabetes, medical professionals, and medical students as well, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 5, the conclusion of this Exclusive Interview, Dr. Mark Huising talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about what he's learned from colleagues and the importance of collaboration.